\-\ Texto\\:\\ \ \(0\)\
\-\ decreased\\ muscle\\ tone\\ all\\ extremities\\.\ \(0\)\
\-\ steroids\\ \\(i\\.v\\.\\ and\\ oral\\)\\ for\\ 6\\ weeks\\ with\\ partial\\ resolution\\ of\\ symptoms\\ and\\ mri\\ findings\\.\ \(0\)\
\-\ \\â\\€\\¢\\ enlarged\\ cervical\\ spinal\\ cord\\.\ \(0\)\
\-\ \\â\\€\\¢\\ high\\ t2\\ signal\\ and\\ low\\ t1\\ signal\\ with\\ mri\\.\ \(0\)\
\-\ \\â\\€\\¢\\ dense\\ multifocal\\ enhancement\\ of\\ medulla\\ and\\ cervical\\ spinal\\ cord\\.\ \(0\)\
\-\ acute\\ disseminated\\ encephalomyelitis\ \(7\)\
\-\ \\â\\€\\¢\\ multiple\\ sclerosis\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ sarcoidosis\ \(1\)\
\-\ \\â\\€\\¢\\ adem\\ \\(acute\\ disseminated\\ encephalomyelitis\\)\ \(0\)\
\-\ 61\\ year\\ old\\ woman\\ with\\ a\\ 6\\ week\\ history\\ of\\ progressive\\ upper\\ and\\ lower\\ extremity\\ weakness\\.\\ \\ now\\,\\ unable\\ to\\ ambulate\\ for\\ past\\ 24\\ hours\\.\\ no\\ history\\ of\\ recent\\ vaccination\\ or\\ viral\\ infection\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ encephalomyelitis\\:\\ 0\\.3323950522139026\ \(0\)\
\-\ disseminated\\:\\ 0\\.3074117340209885\ \(0\)\
\-\ cord\\:\\ 0\\.21039954496895397\ \(0\)\
\-\ cervical\\:\\ 0\\.20329149405612706\ \(0\)\
\-\ spinal\\:\\ 0\\.20154540428216267\ \(0\)\
\-\ vaccination\\:\\ 0\\.1845484171366181\ \(0\)\
\-\ ambulate\\:\\ 0\\.175226334012361\ \(0\)\
\-\ medulla\\:\\ 0\\.16412305618834738\ \(0\)\
\-\ signal\\:\\ 0\\.16090100660361883\ \(0\)\
\-\ acute\\:\\ 0\\.15354676046948249\ \(0\)\
\-\ adem\\:\\ 0\\.15242972953141484\ \(0\)\
\-\ and\\:\\ 0\\.1466303169148564\ \(0\)\
\-\ mri\\:\\ 0\\.14569843431800503\ \(0\)\
\-\ 61\\:\\ 0\\.14405856061062453\ \(0\)\
\-\ tone\\:\\ 0\\.14073640287448227\ \(0\)\
\-\ multifocal\\:\\ 0\\.13780605207530763\ \(0\)\
\-\ viral\\:\\ 0\\.13090926252954807\ \(0\)\
\-\ dense\\:\\ 0\\.12509710577841845\ \(0\)\
\-\ steroids\\:\\ 0\\.124685869534484\ \(0\)\
\-\ unable\\:\\ 0\\.12291505879481897\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.1202179193235179\ \(0\)\
\-\ resolution\\:\\ 0\\.11514805088491116\ \(0\)\
\-\ oral\\:\\ 0\\.11366429696060873\ \(0\)\
\-\ of\\:\\ 0\\.11109258797203594\ \(0\)\
\-\ partial\\:\\ 0\\.10934747933832459\ \(0\)\
\-\ progressive\\:\\ 0\\.1086955845857636\ \(0\)\
\-\ history\\:\\ 0\\.10844343337471599\ \(0\)\
\-\ hours\\:\\ 0\\.10816509057866512\ \(0\)\
\-\ extremities\\:\\ 0\\.1078521402094791\ \(0\)\
\-\ weakness\\:\\ 0\\.10357663877655171\ \(0\)\
\-\ extremity\\:\\ 0\\.10221770845465573\ \(0\)\
\-\ sclerosis\\:\\ 0\\.10108663976156433\ \(0\)\
\-\ muscle\\:\\ 0\\.10077270214108133\ \(0\)\
\-\ 24\\:\\ 0\\.10061720647049288\ \(0\)\
\-\ now\\:\\ 0\\.09742131484257173\ \(0\)\
\-\ enlarged\\:\\ 0\\.09674886238546548\ \(0\)\
\-\ recent\\:\\ 0\\.09609410811605672\ \(0\)\
\-\ week\\:\\ 0\\.09545614428177596\ \(0\)\
\-\ past\\:\\ 0\\.09237925996338117\ \(0\)\
\-\ t1\\:\\ 0\\.08842512765694024\ \(0\)\
\-\ decreased\\:\\ 0\\.08790826017360373\ \(0\)\
\-\ for\\:\\ 0\\.0860298221423222\ \(0\)\
\-\ infection\\:\\ 0\\.08572798818563919\ \(0\)\
\-\ weeks\\:\\ 0\\.08505553572853292\ \(0\)\
\-\ all\\:\\ 0\\.08448168958345895\ \(0\)\
\-\ with\\:\\ 0\\.083369224325158\ \(0\)\
\-\ enhancement\\:\\ 0\\.08168677312149125\ \(0\)\
\-\ t2\\:\\ 0\\.08165058514957411\ \(0\)\
\-\ low\\:\\ 0\\.08143455577802096\ \(0\)\
\-\ high\\:\\ 0\\.08065811974703244\ \(0\)\
\-\ metastatic\\:\\ 0\\.07783610789612942\ \(0\)\
\-\ symptoms\\:\\ 0\\.07765067181052894\ \(0\)\
\-\ upper\\:\\ 0\\.07583993518016112\ \(0\)\
\-\ woman\\:\\ 0\\.07391248295391067\ \(0\)\
\-\ lower\\:\\ 0\\.07252135641637729\ \(0\)\
\-\ findings\\:\\ 0\\.07004329102897223\ \(0\)\
\-\ multiple\\:\\ 0\\.06941623863246911\ \(0\)\
\-\ disease\\:\\ 0\\.059573041092666854\ \(0\)\
\-\ or\\:\\ 0\\.04937149631208135\ \(0\)\
\-\ no\\:\\ 0\\.046150820911201214\ \(0\)\
\-\ year\\:\\ 0\\.043736998905845884\ \(0\)\
\-\ old\\:\\ 0\\.042002658887504714\ \(0\)\
\-\ to\\:\\ 0\\.03547976103391908\ \(0\)\
